Patents Assigned to Jenner Technologies
  • Method to elicit an antitumor response with human prostate-specific antigen
    Patent number: 5925362
    Abstract: Vaccines capable of eliciting an immune antitumor response for prostate tumors are disclosed. The active ingredient in such vaccines is selected from the group consisting of human PSA and expression system capable of generating in situ human PSA.
    Type: Grant
    Filed: August 10, 1994
    Date of Patent: July 20, 1999
    Assignee: Jenner Technologies
    Inventors: Lynn E. Spitler, Anthony E. Maida, III
  • Liposomal formulation
    Patent number: 5820880
    Abstract: Depending on the antigen encapsulated, liposomal formulations are subject to instability in the presence of alum. Formulations containing a nonionic detergent as a stabilizing agent avoid this instability.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 13, 1998
    Assignees: The United States of America as represented by the Secretary of the Army, Jenner Technologies
    Inventors: Carl R. Alving, Jean M. Muderhwa
  • Antitumor vaccines
    Patent number: 5738867
    Abstract: Antitumor vaccine compositions and methods for treating tumors that express the GA733-2 antigen are disclosed. The vaccines comprise a GS733-2 antigen in a liposomal carrier.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: April 14, 1998
    Assignee: Jenner Technologies
    Inventor: Lynn E. Spitler